Compare Sanofi SA (SNY) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Wheaton Precious Metals Corp — how do they compare? Sanofi SA trades at $43.12 (market cap $103.41B), while Wheaton Precious Metals Corp trades at $156 (market cap $71.45B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.65%). Which is the better fit depends on your goals.
| SNY | WPM | |
|---|---|---|
Market Cap | $103.41B | $71.45B |
Sector | Health | Basic Materials |
52-Week High | $52.34 | $165.72 |
52-Week Low | $41.33 | $94.37 |
Enterprise Value | $123.44B | $73.33B |
Dividend Yield | 5.65% | 0.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
Wheaton Precious Metals (WPM) trades at $155.11, up 0.08% with a bullish technical outlook and strong institutional support. The company delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $1.19 beating expectations of $1.15. Revenue surged to $2.31 billion in 2025 with exceptional 64.66% net margins, while cash flow from operations reached $1.90 billion. Analysts maintain 80% buy ratings with a $161.75 consensus target, representing 4.3% upside potential.
WPM's streaming model provides leveraged exposure to precious metals without mining operational risks, supported by fully-funded growth pipeline targeting 50% production increase by 2030. Key risks include commodity price volatility and execution of the ambitious $5.1 billion 2026 investment plan. The stock offers growth potential but requires monitoring of gold/silver price trends and capital deployment efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
